The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).
27 Jan 2023
16 Jan 2023
Eisai has submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) for investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab for early Alzheimer’s Disease (AD) in Japan.
24 May 2022
The US Food and Drug Administration (FDA) has accepted review of a new drug application (NDA) filed by Biohaven Pharmaceutical for zavegepant nasal spray.
10 May 2022
GNS Healthcare and Arvinas have entered into a collaboration for generating insights to help expedite neurodegenerative disease drug development.
25 Aug 2021
Shape Therapeutics has entered into a multi-target strategic collaboration and licence agreement with Roche to develop gene therapy for particular targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases.